title: Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia.
abstract: BACKGROUND
  Abnormal uterine bleeding (AUB) is the most important symptom of endometrial hyperplasia and endometrial curettage (EC) is the gold standard diagnostic procedure. We present the results of patients who underwent EC for AUB and the efficacy of progestin administration in those with endometrial hyperplasia.
  
  
  METHODS
  A total of 415 female patients who presented to Duzce Public Hospital in 2011-2012 for AUB and who underwent EC were included. We determined the reasons for AUB, and females with hyperplasia were treated with 10 mg/day medroxyprogesterone acetate for 14 days/month or 160 mg/day megestrol acetate continuously for 3 months. We evaluated the efficacy of progestins for periods of three and/or six cycles by repeating EC. A statistical analysis of specific endometrial causes according to age of presentation was conducted using the chi-square test.
  
  
  RESULTS
  Among the 415 females (average age, 53.5 years) followed for 6 months, 186 had physiological changes (44.8%), 89 had simple hyperplasia (21.44%), 1 had atypical hyperplasia (0.2%), 6 had (1.44%) complex hyperplasia, 3 had (0.72%) atypical complex hyperplasia, and 5 had adenocarcinoma (1.2%). Regression rates were 72.7-100%, and the optimum results were observed after 6 months of hormonal therapy.
  
  
  CONCLUSIONS
  The main cause of AUB was physiological change. Progestin therapy resulted in significant regression even in females with atypical hyperplasia.
authors.affiliation: Department of Obstetrics and Gynecology, Duzce Public Hospital, Duzce, Turkey E-mail : simendermesci@hotmail.com.
authors.forename: Simender
authors.initials: S
authors.lastname: Mesci-Haftaci
authors.forename: Handan
authors.initials: H
authors.lastname: Ankarali
authors.forename: Ali
authors.initials: A
authors.lastname: Yavuzcan
authors.forename: Mete
authors.initials: M
authors.lastname: Caglar
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003475:Curettage / Q000379:methods; D004714:Endometrial Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000150:complications / Q000175:diagnosis / Q000473:pathology*; D004717:Endometrium / Q000473:pathology*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000473:pathology*; D055815:Young Adult
chemical_list: D017258:Medroxyprogesterone Acetate